Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nasdaq  >  Tricida, Inc.    TCDA

TRICIDA, INC.

(TCDA)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
11/19/2020 11/20/2020 11/23/2020 11/24/2020 11/25/2020 Date
7.52(c) 7.12(c) 7.03(c) 7.43(c) 7.52 Last
1 111 090 1 164 635 456 956 878 487 610 559 Volume
+17.68% -5.32% -1.26% +5.69% +1.21% Change
More quotes
Financials (USD)
Sales 2020 - - -
Net income 2020 -267 M - -
Net cash position 2020 43,4 M - -
P/E ratio 2020 -1,40x
Yield 2020 -
Sales 2021 - - -
Net income 2021 -202 M - -
Net Debt 2021 132 M - -
P/E ratio 2021 -1,90x
Yield 2021 -
Capitalization 373 M 373 M -
EV / Sales 2020 -
EV / Sales 2021 -
Nbr of Employees 157
Free-Float 97,2%
More Financials
Company
Tricida, Inc. is a late-stage pharmaceutical company focused on the discovery and clinical development of non-absorbed therapeutics to address renal, metabolic and cardiovascular disease. The Company's lead program, TRC101 is a treatment for chronic kidney disease (CKD). The Company is engaged in developing a non-absorbed drug to enable safety and efficacy for chronic treatment of CKD patients. The TRC101 drug acts... 
More about the company
Notations Surperformance© of Tricida, Inc.
Trading Rating : Investor Rating : -
More Ratings
All news about TRICIDA, INC.
11/09TRICIDA : MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULT..
AQ
11/09TRICIDA, INC. : Results of Operations and Financial Condition, Financial Stateme..
AQ
11/09TRICIDA : Announces Third Quarter 2020 Financial Results
AQ
11/09Tricida Announces Third Quarter 2020 Financial Results
GL
10/30SHAREHOLDER ALERT : Pomerantz Law Firm Investigates Claims On Behalf of Investor..
PR
10/29TRICIDA : Corporate Investor Presentation, October 2020
PU
10/29TRICIDA, INC. : Costs Associated with Exit or Disposal Activities, Regulation FD..
AQ
10/29TRICIDA : Provides Update on FDA Interactions
BU
10/28TRICIDA : to Provide Update from its End-of-Review Type A Meeting with the FDA
BU
10/09TRICIDA : Announces Twelve Data Presentations on Veverimer and Metabolic Acidosi..
BU
08/31INVESTIGATION ALERT : The Schall Law Firm Announces it is Investigating Claims A..
BU
08/28INVESTIGATION REMINDER : The Schall Law Firm Announces it is Investigating Claim..
BU
08/28ROSEN, A LEADING AND LONGSTANDING LAW FIRM, Announces Investigation of Securi..
BU
08/27TCDA INVESTOR ALERT : Bronstein, Gewirtz & Grossman, LLC Notifies Tricida, Inc. ..
PR
08/26Pomerantz Law Firm Investigates Claims On Behalf of Investors of Tricida, Inc..
PR
More news
News in other languages on TRICIDA, INC.

- No features available -

More news
Chart TRICIDA, INC.
Duration : Period :
Tricida, Inc. Technical Analysis Chart | TCDA | US89610F1012 | MarketScreener
Technical analysis trends TRICIDA, INC.
Short TermMid-TermLong Term
TrendsNeutralBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 4
Average target price 13,00 $
Last Close Price 7,43 $
Spread / Highest target 169%
Spread / Average Target 75,0%
Spread / Lowest Target -19,2%
EPS Revisions
Managers
NameTitle
Gerrit Klaerner President, Chief Executive Officer & Director
Klaus R. Veitinger Chairman
Geoffrey M. Parker Chief Financial Officer & Executive Vice President
Wilhelm Stahl Chief Technology Officer & Senior Vice President
Dawn Parsell Executive Vice President-Clinical Development
Sector and Competitors
1st jan.Capitalization (M$)
TRICIDA, INC.-80.31%373
LONZA GROUP AG56.17%44 950
MODERNA, INC.403.89%39 001
CELLTRION, INC.82.32%36 284
IQVIA HOLDINGS INC.11.32%32 977
SEAGEN INC.44.80%29 684